Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world and ranks third in the number of cancer-related deaths.[@b1-cmar-10-1275],[@b2-cmar-10-1275] Currently, surgical resection remains the primary option for patients with resectable HCC, but the rate of tumor recurrence remains high even after operation due to the refractory property of tumors.[@b3-cmar-10-1275] Therefore, treatments to combat HCC recurrence and metastasis are prioritized. Some strategies have been adopted to suppress HCC metastasis, but they did not show obvious positive effects.[@b4-cmar-10-1275] Therefore, exploring molecular mechanisms and new therapeutic targets is crucial for treating HCC. Unfortunately, there is no clinical tumor marker that provides both satisfactory sensitivity and specificity in the diagnosis and prognosis of HCC. Therefore, it is necessary to study the molecular mechanisms underlying the occurrence and development of HCC and to explore the tumor markers that can ensure an early diagnosis of liver cancer.

Circular RNA (circRNA) is a type of noncoding RNA that exists widely in mammals and is mainly involved in gene regulation in vivo.[@b5-cmar-10-1275]--[@b7-cmar-10-1275] Most circRNAs are derived from the exon regions of the genes, and a small percentage is spliced by introns.[@b8-cmar-10-1275],[@b9-cmar-10-1275] They differ from long noncoding RNA (lncRNA) and microRNAs (miRNAs) in that they do not have the 5′ and 3′ end structures but represent covalently closed cyclic structures.[@b10-cmar-10-1275] CircRNA is widely involved in the regulation of human physiology and pathology by the following three main mechanisms: 1) as an miRNA "sponge" (miRNA sponge), 2) as a protein-binding molecule, and 3) as a template for translation into polypeptides. The mechanisms of miRNA sponge regulation of downstream target genes have been widely reported.[@b11-cmar-10-1275]--[@b13-cmar-10-1275]

Since the global circRNA expression profile in HCC has not been widely studied, in our study, we tested the circRNA expression profile in a cohort of HCC patients. We identified differentially expressed circRNAs in HCC tissues compared with those in paratumorous tissues. hsa_circ_0128298, which is transcribed from ENST00000296695 on chromosome 5, has never been studied before (fold change =127.67, *P*-value =0.006). Therefore, we focused on its association with both the clinicopathological features and prognosis of HCC.

Patients and methods
====================

Patients and samples
--------------------

HCC and paratumor tissues were collected from patients with HCC who underwent surgery at Fudan University Shanghai Cancer Center between January 1, 2011, and December 31, 2015. Informed consent was obtained from the patients before sample collection, in line with the institutional guidelines. The paratumor samples were collected from tissues 3 cm from the edge of the HCC to guarantee the absence of tumor cells. These tissue specimens were immediately placed in RNA fixer reagent and kept at −80°C. Histology was independently assessed by two experienced pathologists who were blinded to the clinical data.

Ethical approval
----------------

The study was approved by the Ethics Committee of Shandong Cancer Hospital affiliated with Shandong University. All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was obtained from all patients before their participation in this clinical research.

RNA isolation, reverse transcription (RT), and quantitative real-time polymerase chain reaction (qRT-PCR)
---------------------------------------------------------------------------------------------------------

Total RNA from all tissues was extracted by using the TRIzol Reagent (Thermo Fisher Scientific, Waltham, MA, USA). All complementary DNAs (cDNAs) were obtained with the GoScriptÔ Reverse Transcription System (Promega Corporation, Fitchburg, WI, USA) following the manufacturer's instructions. The sequences of hsa_circ_0128298 divergent primers were as follows: forward, 5′-TAGACTCAACAGGGCCAAGG-3′; reverse, 5′-TCCATCTTTCTTGAGCAGCA-3′. The primer sequences of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as a control, were 5′-TCGACAGTCAGCCGCATCTTCTTT-3′ and 5′-ACCAAATCCGTTGACTCCGACCTT-3′. These primers were synthesized by the PrimerBank. To determine the reproducibility of the qRT-PCR method for detecting the hsa_circ_0000520 levels in HCC tissue, we performed qRT-PCR three times to measure the differences between experimental batches. The data from qRT-PCR were analyzed by the ΔCt method. All results were expressed as the mean ± SD. All assays were performed in a blinded fashion.

Microarray data analysis
------------------------

The microarray detection was performed by Boao Bio-Tech (Beijing, China) under the guidance of the experiment work flow. The human 8×15K CIRCRNA Array was manufactured by Arraystar Technologies (Rockville, MD, USA). Overall, 65521 circRNAs were detected. Each circRNA was accurately identified using a specific probe targeting the circRNA-specific junction. Sample labeling, array hybridization, and raw data extraction were done with a high-quality control. Quantile normalization of raw data and subsequent data processing was performed using the R software package (R Version 3.1.2).

Statistical analyses
--------------------

All statistical analyses were performed by the Statistical Product and Service Solutions (SPSS) 22.0 software package (IBM Corporation, Armonk, NY, USA) and Graph-Pad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA). The differences in the levels of hsa_circ_0128298 between HCC and paired adjacent nontumorous tissues were assessed using the Student's *t*-test for paired data. Spearman's rank correlation coefficient was introduced to further calculate bivariate correlations. The receiver operating characteristic (ROC) curve was established to evaluate its diagnostic value. Independent prognostic factors for patient outcome were identified using the Cox regression model. The overall survival (OS) data were analyzed using the Kaplan--Meier method, and the differences were evaluated using log-rank tests. Two-sided *P*-values \<0.05 were considered statistically significant.

Results
=======

Overview of circRNA profiles in HCC tissues
-------------------------------------------

Our microarray analysis revealed the circRNA expression profiles, as tested from three paired human HCC and paratumorous tissues. The detailed experimental process is shown in [Figure 1](#f1-cmar-10-1275){ref-type="fig"}, and clinicopathological characteristics are shown in [Table 1](#t1-cmar-10-1275){ref-type="table"}. The median follow-up time was 37 months. The heat-map is depicted as a direct approach to visualize the distributions of the dataset for the circRNAs profiles ([Figure 2A and B](#f2-cmar-10-1275){ref-type="fig"}). The circRNA expression patterns between HCC and paratumorous tissues were found to be significantly different ([Figure 2C](#f2-cmar-10-1275){ref-type="fig"}). Differentially expressed circRNAs with statistical significance (fold changes ≥2.0 and *P*\<0.05) between groups were identified by volcano plot filtering ([Figure 2D](#f2-cmar-10-1275){ref-type="fig"}). After screening the differential circRNA expression profiles, we selected hsa_circ_0128298 and hsa_circ_0091582, the two most-changed circRNAs, for further study. We chose these two circRNAs for the following two reasons: 1) these two circRNAs had not been studied previously and 2) both circRNAs were in the top 10 highly expressed circRNAs.

hsa_circ_0128298 was upregulated in HCC tissues
-----------------------------------------------

qRT-PCR was used to detect the hsa_circ_0128298 and hsa_circ_0091582 expression levels in liver tissues from HCC patients. In the initial verification process with 30 pairs of HCC and paratumor tissues, hsa_circ_0091582 and hsa_circ_0128298 were upregulated in HCC tissues (*P*=0.023 and 0.024, respectively) ([Figure 3](#f3-cmar-10-1275){ref-type="fig"}). In the extended verification process with 78 pairs of samples, only hsa_circ_0128298 was upregulated (*P*=0.006) ([Figures 4](#f4-cmar-10-1275){ref-type="fig"} and S1).

Upregulation of hsa_circ_0128298 is associated with clinicopathological factors in HCC patients
-----------------------------------------------------------------------------------------------

The data presented earlier demonstrated that the hsa_circ_0128298 expression was significantly upregulated in HCC tissues; hence, we analyzed the association between its expression and clinicopathological factors of patients with HCC.

As shown in [Table 2](#t2-cmar-10-1275){ref-type="table"}, in HCC tissues, a significant association was observed between the hsa_circ_0128298 expression and vascular cancer embolus (*P*=0.012), lymphatic metastasis (*P*=0.018), and organ metastasis (*P*=0.048). However, no association was found between the hsa_circ_0128298 expression and other clinicopathological factors, including gender (*P*=0.455), age (*P*=0.112), hepatitis Bs antigen (*P*=0.615), hepatitis Be antigen (*P*=0.761), cirrhosis (*P*=0.65), AFP (*P*=0.226), and intrahepatic metastasis (*P*=0.11). The Spearman analysis in [Table 3](#t3-cmar-10-1275){ref-type="table"} indicated that the expression of hsa_circ_0128298 was correlated with intrahepatic metastasis (*P*=0.021), lymphatic invasion (*P*=0.004), and organ metastasis (*P*=0.021).

Potential diagnostic values of hsa_circ_0128298
-----------------------------------------------

The ROC curve was used to investigate the diagnostic value of hsa_circ_0128298 in distinguishing HCC tissues from paratumorous tissues. In the initial verification, we found that the proportion of hsa_circ_0091582 and hsa_circ_0128298 under the ROC curve (area under the curve \[AUC\]) was 0.679 and 0.664 (*P*=0.017 and 0.029, respectively) ([Figure 3](#f3-cmar-10-1275){ref-type="fig"}). In the extended verification, only hsa_circ_0128298 was confirmed to have the diagnostic value of AUC =0.668 (*P*\<0.001) ([Figure 4A](#f4-cmar-10-1275){ref-type="fig"} and B). The sensitivity and specificity were 0.674 and 0.805, respectively.

Potential prognostic values of hsa_circ_0128298
-----------------------------------------------

We analyzed all clinicopathological characteristics and hsa_circ_0128298 expression levels in the prognosis of HCC. Cox regression analysis was used to determine whether hsa_circ_0128298 could serve as a prognostic factor. The univariate analysis showed that the gender (*P*=0.018), AFP (*P*=0.004), intrahepatic metastasis (*P*=0.003), organ metastasis (*P*=0.005), and hsa_circ_0128298 expression (*P*=0.009) were independent factors ([Table 4](#t4-cmar-10-1275){ref-type="table"}). Multivariate Cox regression analysis found that the AFP level (*P*=0.018) and hsa_circ_0128298 expression level (*P*=0.014) were the prognostic factors predicting poor survival among HCC patients ([Table 4](#t4-cmar-10-1275){ref-type="table"}).

We further examined whether the hsa_circ_0128298 expression level was correlated with the outcome of HCC patients after hepatectomy. Kaplan--Meier's survival curves were used to compare the low (n=39) and high (n=39) hsa_circ_0128298 subgroups, and the results are presented in [Figure 5](#f5-cmar-10-1275){ref-type="fig"}. Patients with higher hsa_circ_0128298 expression levels had a statistically significant difference in the OS compared to the low expression group (*P*=0.003).

Discussion
==========

In recent years, there have been few advances in the treatment of HCC. Clinically, surgery and systemic chemotherapy are the standard treatments for HCC.[@b3-cmar-10-1275] However, only 13--15% of patients with HCC are suitable for surgery. Most patients are diagnosed with an advanced HCC, losing the precious opportunity for surgical operation. In addition, patients with HCC are prone to be multidrug resistant.[@b3-cmar-10-1275] There are several challenges in the diagnosis and treatment of HCC. First, there are difficulties in early diagnosis. Among the clinicopathological characteristics of HCC is its lack of specific early symptoms. Furthermore, the resection rate is only 15%, but \~50% patients are found to have distant metastases during treatment.[@b14-cmar-10-1275] Second, the heterogeneity of HCC further increases the difficulty. The genome-wide analysis of HCC has shown that genetic changes exist in \>10 core signaling pathways. It has been reported that the alterations of multiple genes could possibly lead to ineffective treatments, resulting in poor prognosis.[@b15-cmar-10-1275] Therefore, the diagnosis and treatment of HCC should rely on early detection and diagnosis. The detection of HCC-related molecular markers predicting the early occurrence of HCC could be a more pragmatic way to diagnose and treat HCC.

Increasing numbers of studies have shown that noncoding RNAs play an important role in the development of cancer.[@b5-cmar-10-1275]--[@b9-cmar-10-1275],[@b11-cmar-10-1275] However, there are few studies on circRNA. circRNA is a type of special noncoding RNA and is the latest research hotspot in the RNA field. Unlike traditional linear RNAs (including 5′ and 3′ ends), circRNAs are closed-loop structures that are not affected by RNA exo-enzymes and are more stable and less degradable.[@b7-cmar-10-1275] Functionally, recent studies have shown that circRNAs are enriched at the miRNA-binding sites and play the role of miRNA sponges in cells, thus releasing the inhibitory effect of miRNAs on their target genes and increasing the target gene expression, which is known as the competitive endogenous RNA (ceRNA) mechanism.[@b16-cmar-10-1275],[@b17-cmar-10-1275] In addition, circRNAs play an important regulatory role in cancer via their interaction with cancer-associated miRNAs.[@b18-cmar-10-1275]

Here, we identified a new circRNA (hsa_circ_0128298) that was significantly upregulated in HCC tissues. The expression of hsa_circ_0128298 was significantly associated with vascular cancer embolus, lymph node (LN), and organ metastasis (*P*\<0.05). The Spearman analysis of correlation between hsa_circ_0128298 and various clinicopathological factors indicated that the expression of hsa_circ_0128298 was correlated with intrahepatic metastasis, LN metastasis, and organ metastasis (*P*\<0.05). Moreover, we found that HCC patients with lower expression levels of hsa_circ_0128298 have prolonged OS compared to patients with higher hsa_circ_0128298 expression levels. The ROC analysis proved that hsa_circ_0128298 could be recognized as an HCC biomarker with favorable sensitivity and specificity. Note, in the Spearman analysis, hsa_circ_0128298 was negatively correlated with the three metastatic indicators, which is inconsistent with other results. Considering that hsa_circ_0128298 was an indicator of prognosis in HCC, we speculated that hsa_circ_0128298 did not affect the patients' prognosis by promoting metastasis. It might affect the prognosis of patients through other phenotypes, such as promoting vascular proliferation/immune escape. This also provides a certain direction for future research on the functional experiments of hsa_circ_0128298.

However, only 78 pairs of HCC tissues were analyzed in this study because of the limited number of available HCC samples. In addition, the tumor staging, T staging, and N staging were not included in our study due to a failure to acquire this information from some HCC patients. A larger number of samples should be tested at multiple centers to further confirm our conclusion. Furthermore, we did not test the molecular biological effects of hsa_circ_0128298 on HCC in vivo and in vitro.

Conclusion
==========

Our data indicate that hsa_circ_0128298 expression is significantly upregulated in HCC samples and is a predictor of HCC occurrence and prognosis. Therefore, hsa_circ_0128298 could serve as a potential biomarker in the diagnosis of HCC and as a prognostic marker for the survival of HCC patients.

Supplementary material
======================

###### 

The expression levels and diagnostic value of hsa_circ_0091528.

**Abbreviation:** AUC, area under the curve.
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![The detailed experimental process.\
**Notes:** circRNA expression profiles were screened in three paired human HCC and paratumorous tissues. Targeted circRNAs were verified by qRT-PCR via initial verification in 30 pairs of samples and extended verification in 78 pairs of samples.\
**Abbreviations:** circRNAs, circular RNAs; HCC, hepatocellular carcinoma; qRT-PCR, quantitative real-time polymerase chain reaction.](cmar-10-1275Fig1){#f1-cmar-10-1275}

![Overview of the microarray signatures.\
**Notes:** (**A**) Unsupervised clustering analysis clearly distinguished the tumors and their corresponding nontumorous samples. (**B**) Illustration of the human genome showing the overall expression profile of the samples. (**C**) The whole transcriptome profiles of the tumor and their adjacent paratumor tissues were highly correlated. (**D**) Volcano plot showing the significantly deregulated genes in tumor samples.](cmar-10-1275Fig2){#f2-cmar-10-1275}

![Target circRNAs from the initial verification from 30 pairs of samples.\
**Notes:** (**A** and **B**) Increased expression of hsa_circ_0091582 and hsa_circ_0128298 in HCC tissues. RT-PCR was used to determine the expression levels. The ΔCt values were determined by subtracting the Ct value for GAPDH from the Ct values for circRNAs. Larger ΔCt values indicate higher expression (n=30, *P*=0.023 and n=30, *P*=0.024, respectively). (**C** and **D**) The ROC curve for using hsa_circ_0091582 and hsa_circ_0128298 as biomarkers (*P*=0.017 and 0.029, respectively).\
**Abbreviations:** circRNAs, circular RNAs; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HCC, hepatocellular carcinoma; ROC, receiver operating characteristics; RT-PCR, real-time polymerase chain reaction; AUC, area under the curve.](cmar-10-1275Fig3){#f3-cmar-10-1275}

![The expression levels and diagnostic value of hsa_circ_0128298.\
**Notes:** (**A**) Increased expression of hsa_circ_0128298 in HCC tissues (*P*=0.006). (**B**) The ROC curve of using hsa_circ_0128298 as a biomarker (*P*\<0.001, AUC =0.668).\
**Abbreviations:** AUC, area under the curve; ROC, receiver operating characteristics.](cmar-10-1275Fig4){#f4-cmar-10-1275}

![hsa_circ_0128298 can be an independent prognostic factor to predict OS.\
**Note:** Kaplan--Meier's analyses of correlations between the hsa_circ_0128298 expression levels and OS of 78 HCC patients are shown.\
**Abbreviations:** HCC, hepatocellular carcinoma; OS, overall survival.](cmar-10-1275Fig5){#f5-cmar-10-1275}

###### 

Clinicopathological characteristics of patient samples and expression of hsa_circ_0128298 in hepatocellular carcinoma

  Variable                  n
  ------------------------- ---------
  Gender                    
  M/F                       70/8
  Age (years)               37 (41)
  ≥55/\<55                  
  Vascular cancer embolus   
  Yes/no                    48/29
  HBSAG                     
  Positive/negative         65/13
  HBEAB                     
  Positive/negative         65/13
  Cirrhosis                 
  Yes/no                    36/42
  AFP                       
  ≥20/\<20                  52/26
  Intrahepatic metastasis   
  Yes/no                    23/55
  LN metastasis             
  Yes/no                    19/59
  Organ metastasis          
  Yes/no                    7/71
  Expression                
  Low/high                  39/39

**Abbreviations:** F, female; LN, lymph node; M, male; HBSAG, hepatitis Bs antigen; HBEAG, hepatitis Be antigen.

###### 

Correlation between hsa_circ_0128298 expression and clinicopathological characteristics of hepatocellular carcinoma patients

  Characteristics           High expression   Low expression   *P*-value
  ------------------------- ----------------- ---------------- -----------
  Gender                                                       
  M/F                       34/5              36/3             0.455
  Age (years)                                                  
  ≥55/\<55                  22/17             15/24            0.112
  Vascular cancer embolus                                      
  Yes/no                    29/9              19/20            0.012
  HBSAG                                                        
  Positive/negative         29/10             27/12            0.615
  HBEAB                                                        
  Positive/negative         32/7              33/6             0.761
  Cirrhosis                                                    
  Yes/no                    19/20             17/22            0.650
  AFP                                                          
  ≥20/\<20                  43343             26/13            0.226
  Intrahepatic metastasis                                      
  Yes/no                    15/24             8/29             0.110
  LN metastasis                                                
  Yes/no                    14/25             5/34             0.018
  Organ metastasis                                             
  Yes/no                    6/33              1/38             0.048

**Abbreviations:** F, female; LN, lymph node; M, male; HBSAG, hepatitis Bs antigen; HBEAG, hepatitis Be antigen.

###### 

Spearman analysis of correlation between hsa_circ_0128298 and clinicopathological characteristics

  Variables                 hsa_circ_0128298 expression level   
  ------------------------- ----------------------------------- -------
  Gender                    −0.101                              0.07
  Age                       0.093                               0.418
  Vascular cancer embolus   0.143                               0.216
  HBSAG                     0.149                               0.165
  HBEAB                     0.055                               0.632
  Cirrhosis                 −0.084                              0.466
  AFP                       0.058                               0.617
  Intrahepatic metastasis   −0.244                              0.034
  LN metastasis             −0.323                              0.004
  Organ metastasis          −0.264                              0.019

**Abbreviations:** LN, lymph node; HBSAG, hepatitis Bs antigen; HBEAG, hepatitis Be antigen.

###### 

Univariate and multivariate analyses of various prognostic parameters in patients with HCC (Cox regression analysis)

  Variables                     Univariate analysis   Multivariate analysis                                  
  ----------------------------- --------------------- ----------------------- -------------- ------- ------- --------------
  Gender                        0.018                 3.268                   1.220--8.750                   
  Age                           0.944                 1.001                   0.972--1.031                   
  Vascular cancer embolus       0.08                  0.513                   0.243--1.084                   
  HBSAG                         0.055                 2.415                   0.920--5.207                   
  HBEAB                         0.312                 1.511                   0.679--3.364                   
  Cirrhosis                     0.454                 0.773                   0.394--1.518                   
  AFP                           0.004                 4.25                    1.420--4.329   0.018   1.251   1.032--3.989
  Intrahepatic metastasis       0.003                 1.343                   1.144--7.056                   
  LN metastasis                 0.387                 0.703                   0.316--1.562                   
  Organ metastasis              0.005                 0.244                   0.091--0.657                   
  hsa_circ_0128298 expression   0.009                 1.978                   1.341--3.024   0.014   6.661   2.661--8.418

**Abbreviations:** LN, lymph node; HBSAG, hepatitis Bs antigen; HBEAG, hepatitis Be antigen.
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